Xinwei Medical

Shanghai Xinwei Medical Technology Joint-stock Co., Ltd. (hereinafter referred to as Xinwei Medical) was established in 2016. It is a high-tech medical innovative company with independent intellectual property rights, focusing on the development and industrialization of minimally invasive interventional new technologies for the prevention and treatment of stroke. From the beginning, we have implemented the concept of "Heart-Brain Co-treatment, Stroke Prevention" advocated by the National Stroke Prevention Committee, and are determined to become a globally leading company providing overall solutions for stroke treatment and prevention. Listening to patients' voices, combining real clinical needs, and adhering to the original aspiration of "Heart and Brain Health, Innovative Protection," we work together with clinical experts in cardiovascular and cerebrovascular fields to develop technologies and products that better meet clinical needs and are more affordable for global stroke patients, fulfilling Xinwei Medical's mission and pursuit of "Protecting Life and Health with Heart." Xinwei Medical is based on innovative technology research and development, academic promotion, and treatment popularization. It has built a management team integrating production, education, and research, as well as a complete product line covering stroke prevention and treatment, including five major categories: "Thrombectomy for ischemic stroke, Treatment for ischemic stroke stenosis, Treatment for hemorrhagic stroke, Prevention of cardiogenic stroke, and Vascular access products." The company has received support from Shanghai's major strategic emerging industry projects and multiple research and development funds from the municipal and district levels, and won the first prize in the 2020 China Medical Device Industry Innovation and Entrepreneurship Competition.